Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs
Virginia Metrangolo, Lars H. Engelholm
Cancers (2024) Vol. 16, Iss. 2, pp. 447-447
Open Access | Times Cited: 25

Showing 25 citing articles:

Antibody–Drug Conjugates—Evolution and Perspectives
Adriana Aurelia Chiș, Carmen Maximiliana Dobrea, Anca Maria Arseniu, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 6969-6969
Open Access | Times Cited: 5
Antibody-Drug Conjugates in Urothelial Cancer: From Scientific Rationale to Clinical Development
Whi‐An Kwon, Seo Yeon Lee, Tae Cheon Jeong, et al.
Cancers (2024) Vol. 16, Iss. 13, pp. 2420-2420
Open Access | Times Cited: 5
Targeting uPAR with an antibody-drug conjugate suppresses tumor growth and reshapes the immune landscape in pancreatic cancer models
Virginia Metrangolo, Mylan Blomquist, Ananya Dutta, et al.
Science Advances (2025) Vol. 11, Iss. 3
Open Access
Challenges and opportunities in single-domain antibody-based tumor immunotherapy
Xiaozhi Xi, Guo Shu-hua, Yuchao Gu, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2025), pp. 189284-189284
Closed Access
Prospects for the Use of Antibody-Drug Conjugates in Cancer Therapy
A. O. Makarova, E. V. Svirshchevskaya, Mikhail Titov, et al.
Russian Journal of Bioorganic Chemistry (2025) Vol. 51, Iss. 2, pp. 556-573
Closed Access
Epidermal Growth Factor Receptor Targeting in Colorectal Carcinoma: Antibodies and Patient-Derived Organoids as a Smart Model to Study Therapy Resistance
Samuele Tardito, Serena Matis, Maria Raffaella Zocchi, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 13, pp. 7131-7131
Open Access | Times Cited: 4
Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics
Arya Bhushan, Preeti Misra
Current Oncology Reports (2024) Vol. 26, Iss. 10, pp. 1224-1235
Closed Access | Times Cited: 4
Single-Domain Antibodies as Antibody–Drug Conjugates: From Promise to Practice—A Systematic Review
Víctor Manuel Medina Pérez, Marta Baselga, Alberto J. Schuhmacher
Cancers (2024) Vol. 16, Iss. 15, pp. 2681-2681
Open Access | Times Cited: 4
Contemporary Approaches to Immunotherapy of Solid Tumors
A. V. Kuznetsova, Ksenia А. Glukhova, О. П. Попова, et al.
Cancers (2024) Vol. 16, Iss. 12, pp. 2270-2270
Open Access | Times Cited: 3
Recent advancements in nanomedicine as a revolutionary approach to treating multiple myeloma
Fatemeh Sadat Shafiei, Saeid Abroun
Life Sciences (2024) Vol. 356, pp. 122989-122989
Closed Access | Times Cited: 3
Evaluating the Potential of Cyclodextrins in Reducing Aggregation of Antibody–Drug Conjugates with Different Payloads
Florian Johann, Steffen Wöll, Henning Gieseler
Journal of Pharmaceutical Sciences (2024) Vol. 113, Iss. 8, pp. 2443-2453
Open Access | Times Cited: 2
Advancing Treatment Options for Merkel Cell Carcinoma: A Review of Tumor-Targeted Therapies
Helena M. Nammour, Karla Madrigal, Caroline T. Starling, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 20, pp. 11055-11055
Open Access | Times Cited: 2
Late-Stage Desulfurization Enables Rapid and Efficient Solid-Phase Synthesis of Cathepsin-Cleavable Linkers for Antibody–Drug Conjugates
Marzieh Ahangarpour, Margaret A. Brimble, Iman Kavianinia
Bioconjugate Chemistry (2024) Vol. 35, Iss. 7, pp. 1007-1014
Closed Access | Times Cited: 1
Risk Evaluation of N-Nitrosamines in Drug-Linker Intermediates Used To Generate Antibody–Drug Conjugates
Osama Chahrour, Paul G. Bulger, Olivier Dirat, et al.
Organic Process Research & Development (2024) Vol. 28, Iss. 8, pp. 3085-3093
Closed Access | Times Cited: 1
Antibody-drug Conjugates in Cancer Treatment: An Overview
Nikita Gupta, L. Sai Geethika, Payavula Sneha
Journal of Cancer and Tumor International (2024) Vol. 14, Iss. 3, pp. 33-45
Open Access | Times Cited: 1
Kinetic Modeling of the Antibody Disulfide Bond Reduction Reaction With Integrated Prediction of the Drug Load Profile for Cysteine‐Conjugated ADCs
Jan Tobias Weggen, Pedro González, Kimberly Hui, et al.
Biotechnology and Bioengineering (2024)
Open Access | Times Cited: 1
Synthesis and evaluation of Antibody-Drug conjugates with high Drug-to-Antibody ratio using Dimaleimide-DM1 as a linker- payload
Joo‐Hyun Jeon, Seo Woo Kim, Yun Joong Kim, et al.
Bioorganic Chemistry (2024) Vol. 149, pp. 107504-107504
Open Access
New drugs beyond immunotherapy in squamous head and neck cancer
Alfonso Berrocal Jaime, A.J. Cunquero Tomás
Revisiones en Cáncer (2024)
Closed Access
Advances in immunotoxin engineering: precision therapeutic strategies in modern oncology
Akbar Oghalaie, Mahmoud Eshagh Hosseini, Mohammad Hosseininejad-Chafi, et al.
Medical Oncology (2024) Vol. 41, Iss. 10
Closed Access
Technical, Preclinical, and Clinical Developments of Fc Glycan-Specific Antibody-drug Conjugates
Qiang Yang, Yunpeng Liu
RSC Medicinal Chemistry (2024)
Open Access
Towards Aptamer-Targeted Drug Delivery to Brain Tumors: The Synthesis of Ramified Conjugates of an EGFR-Specific Aptamer with MMAE on a Cathepsin B-Cleavable Linker
Vladimir A. Brylev, Ekaterina V. Ryabukhina, Evgeniya V. Nazarova, et al.
Pharmaceutics (2024) Vol. 16, Iss. 11, pp. 1434-1434
Open Access
Branched Linkers for Homogeneous Antibody-Drug Conjugates: How Long Is Long Enough?
Evgeny L. Gulyak, О. В. Комарова, Yuri Prokopenko, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 24, pp. 13356-13356
Open Access
Unlocking the potential of melanotransferrin (CD228): implications for targeted drug development and novel therapeutic avenues
Yanan Zhang, Deyong Song, Xiaolei Han, et al.
Expert Opinion on Therapeutic Targets (2024)
Closed Access
Unlocking Natural Potential: Antibody‐Drug Conjugates With Naturally Derived Payloads for Cancer Therapy
Xue Jiang, Wan Najbah Nik Nabil, Yufei Ze, et al.
Phytotherapy Research (2024)
Closed Access
Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy
Rositsa Mihaylova, Denitsa Momekova, Viktoria Elincheva, et al.
Pharmaceuticals (2024) Vol. 17, Iss. 12, pp. 1701-1701
Open Access
Page 1

Scroll to top